Digestive and Liver Disease最新文献_第2页

Pancreatic fat density and post-ERCP pancreatitis: A complex relationship or a novel predictor?

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-11 DOI: 10.1016/j.dld.2025.02.019

Amir Farah, Amir Mari

引用次数: 0

Author's reply: "Navigating anti-TNF therapy risks: Real-world insights on pregnancy, breastfeeding, and vaccines in IBD patients".

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-11 DOI: 10.1016/j.dld.2025.02.006

Pauline Wils, Marion Simon, Anthony Buisson

引用次数: 0

Endoscopic healing in IBD: Still the target to achieve?

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-11 DOI: 10.1016/j.dld.2025.02.009

Andrea Buda, Tommaso Pessarelli, Giovanni Aldinio, Manuela De Bona, Marietta Iacucci, Gian Eugenio Tontini

引用次数: 0

Occupational toxicants in MASLD: Bias, complexity, and future directions.

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-10 DOI: 10.1016/j.dld.2025.02.020

Bernardo Stefanini, Francesco Tovoli

引用次数: 0

A two-transcript classifier model for assessing disease activity in patients with ulcerative colitis: A discovery and validation study.

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-10 DOI: 10.1016/j.dld.2025.02.015

Huipeng Zhang, Nannan Xu, Gang Huang, Guanwei Bi, Jing Zhang, Xiaohan Zhao, Xinrui Guo, Miaolin Lei, Gang Wang, Yanbo Yu

{"title":"A two-transcript classifier model for assessing disease activity in patients with ulcerative colitis: A discovery and validation study.","authors":"Huipeng Zhang, Nannan Xu, Gang Huang, Guanwei Bi, Jing Zhang, Xiaohan Zhao, Xinrui Guo, Miaolin Lei, Gang Wang, Yanbo Yu","doi":"10.1016/j.dld.2025.02.015","DOIUrl":"https://doi.org/10.1016/j.dld.2025.02.015","url":null,"abstract":"Aims: We aimed to develop and validate classifier models to assess disease activity in UC patients by evaluating potential classifier genes expression levels.Methods: The study comprised UC and healthy control participants undergoing colonoscopy. We screened candidate genes (TGF-β1, CEACAM1 and CD177) using Differentially Expressed Genes. We compared candidate genes expression levels with the validated UC scores. UC patients were subsequently randomly assigned (1:1) to the discovery or validation groups. A logistic regression model integrating candidate genes expression was developed using discovery group and assessed its predictive effect in validation group.Results: Three candidate genes were differentially associated with UC disease activity. TGF-β1 and CD177 were used to construct the logistic regression model. The two-transcript classifier model had an area under the receiver operating curve (AUC) of 0.938 (95 % confidence interval [CI]=0.888-0.987) in discriminating between remission and active UC and an AUC of 0.919 (0.862-0.977) in discriminating between remission-mild and moderate-severe activity in UC.Conclusions: TGF-β1 and CD177 transcript levels, measured by RT-PCR, are robust classifiers for assessing disease activity in UC patients, and the measurement of these transcript levels appears to be an effective method of monitoring condition of UC patients and predicting treatment effectiveness over time.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author's reply: "Predictors for the development of diabetes mellitus following acute pancreatitis".

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-10 DOI: 10.1016/j.dld.2025.02.021

Gila Ginzburg, Maisam Abu-El-Haija

引用次数: 0

AI-based measurement of adipose body composition in patients with acute pancreatitis: The holy grail to define the prognosis?

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-10 DOI: 10.1016/j.dld.2025.02.012

Antonio Facciorusso, Enrique De-Madaria

引用次数: 0

From data to practice: The necessity of optimizing ustekinumab treatment strategies.

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-08 DOI: 10.1016/j.dld.2025.02.022

FaYuan Wang, Ping He

引用次数: 0

Comment on "The crackers challenge": A reassuring low-dose gluten challenge in adults on gluten-free diet without proper diagnosis of coeliac disease".

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-06 DOI: 10.1016/j.dld.2025.02.003

Esmaeil Hamzehnava, Mohammadreza Ahmadi, Ali Hosseini

引用次数: 0

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).

IF 4 3区医学

Digestive and Liver Disease Pub Date : 2025-03-04 DOI: 10.1016/j.dld.2025.02.002

Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, Christophe Tournigand, Michel Ducreux, David Tougeron, Côme Lepage, Laurent Mineur, Philippe Laplaige, Romain Desgrippes, Pascal Artru, Christophe Borg, Marine Jary, Olivier Bouché, Jean-Philippe Metges, Rosine Guimbaud, Thomas Aparicio, Fanny Foubert, Vincent Hautefeuille, Marie Muller, Karine Bouhier-Leporrier, Rémi Darrius, Sarah Lobet, Fanny Monmousseau, Théodora Bejan-Angoulvant, Gilles Paintaud, David Ternant

{"title":"Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).","authors":"Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, Christophe Tournigand, Michel Ducreux, David Tougeron, Côme Lepage, Laurent Mineur, Philippe Laplaige, Romain Desgrippes, Pascal Artru, Christophe Borg, Marine Jary, Olivier Bouché, Jean-Philippe Metges, Rosine Guimbaud, Thomas Aparicio, Fanny Foubert, Vincent Hautefeuille, Marie Muller, Karine Bouhier-Leporrier, Rémi Darrius, Sarah Lobet, Fanny Monmousseau, Théodora Bejan-Angoulvant, Gilles Paintaud, David Ternant","doi":"10.1016/j.dld.2025.02.002","DOIUrl":"https://doi.org/10.1016/j.dld.2025.02.002","url":null,"abstract":"Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to a standard dose, increases efficacy in mCRC patients treated with bevacizumab-based chemotherapy as first-line therapy and who have a low initial trough concentration of bevacizumab. PHARBEVACOL is a multicenter, randomized, double-blind, two-parallel group trial. All patients will receive first-line bi-weekly 5 mg/kg bevacizumab-based chemotherapy and those with low initial bevacizumab concentrations (≤15.5 mg/L) will be randomized to either continue the standard dose (5 mg/kg every 14 days) or receive a double dose (10 mg/kg every 14 days). The primary objective is to evaluate the effect of doubling dose on progression-free survival (PFS). During a screening phase, the first serum trough concentration will be measured on day 14, before the second infusion of bevacizumab. We hypothesize a 40 % PFS in the control group at 9 months versus 60 % in the study group, corresponding to a hazard ratio of 0.56. With 80 % power, a 5 % two-sided type I error, and a minimum 12-month follow-up, 116 patients need to be included. Since only 50 % of screened patients will be eligible for randomization, approximately 244 patients will be screened. Recruitment is scheduled to begin in February 2025.","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":" ","pages":""},"PeriodicalIF":4.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0